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Abstract
Human breast cancer has been characterized by extensive transcriptional heterogeneity,
with dominant patterns reflected in the intrinsic subtypes. Mouse models of breast cancer
also have heterogeneous transcriptomes and we noted that specific histological subtypes
were associated with particular subsets. We hypothesized that unique sets of genes define
each tumor histological type across mouse models of breast cancer. Using mouse models
that contained both gene expression data and expert pathologist classification of tumor his-
tology on a sample by sample basis, we predicted and validated gene expression signatures
for Papillary, EMT, Microacinar and other histological subtypes. These signatures predict
known histological events across murine breast cancer models and identify counterparts of
mouse mammary tumor types in subtypes of human breast cancer. Importantly, the EMT,
Adenomyoepithelial, and Solid signatures were predictive of clinical events in human breast
cancer. In addition, a pan-cancer comparison revealed that the histological signatures were
active in a variety of human cancers such as lung, oral, and esophageal squamous tumors.
Finally, the differentiation status and transcriptional activity implicit within these signatures
was identified. These data reveal that within tumor histology groups are unique gene
expression profiles of differentiation and pathway activity that stretch well beyond the trans-
genic initiating events and that have clear applicability to human cancers. As a result, our
work provides a predictive resource and insights into possible mechanisms that govern
tumor heterogeneity.
Author summary
We developed predictive gene signatures that identify specific histological mouse mam-
mary tumor subtypes with high fidelity to expert pathologist classifications. As a result,
these signatures are a powerful tool for classification, particularly in cases of intratumor
heterogeneity; where confounding results arise from differences in the tumor portions
sent for pathology and separately for molecular analysis. Further, we show that despite dif-
ferences in the tumor initiating oncogene, histological subtypes in mouse mammary
tumor are unified in their transcriptomic profiles and activation of cell signaling
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pathways. We find that these transcriptomic profiles and activation of key signaling path-
ways are not only conserved in human breast cancer, but also other human cancer types.
Further, the EMT, Adenomyoepithelial and Solid signatures were prognostic in specific
human breast cancer subtypes. Indeed, this work provides a new and needed perspective
on how mouse models relate to specific human breast cancer subtypes by showing that
the tumor histology of the mouse mammary tumor is far more important than the initiat-
ing oncogenic event in terms of how the mouse mirrors a specific human subtype.
Introduction
One of the hallmarks of breast cancer is tumor heterogeneity at both the histological and geno-
mic level. The histological type of the tumor refers to the morphological and cytological pat-
terns evident within a tumor. There are a large number of special tumor histologies recognized
for breast cancer [1, 2] including lobular, cribriform and several other types. The most fre-
quently observed tumor histology is the invasive ductal carcinoma [3]. Similarly, there is a
large degree of genomic heterogeneity in human breast cancer, which has been classified using
gene expression analysis. Classification of breast tumors into their molecular subtypes based
on unique gene expression profiles has led to tumors being described according to their
“intrinsic subtype”: Basal-like, Luminal A, Luminal B, Her-2 enriched, Claudin Low and Nor-
mal-like breast group [4–6]. Importantly, these intrinsic subtypes of breast cancer provide a
basis by which researchers can classify tumor heterogeneity.
Importantly, recent work has identified the gene expression relationships between intrinsic
subtypes of human breast cancer and specific histological types of breast cancer [2]. Chief
amongst their findings was that within intrinsic subtypes of cancer were multiple histological
types of cancer. For example, both medullary and metaplastic breast cancer were categorized
as claudin low. Further, individual tumors of the same tumor histological types corresponded
to different intrinsic subtypes of breast cancer. For example, some medullary tumors were clas-
sified as basal and others were categorized as claudin low. These findings suggest that gene
expression methods may do better job of organizing tumors into similar disease entities[2].
Collectively, these studies demonstrate that histological and genomic heterogeneity present in
breast cancer establishes a complex array of distinct subtypes of tumors[2, 4].
With this complexity, modeling breast cancer in vivo requires numerous preclinical models
that effectively mimic the multiple factors inherent to human breast cancer progression and
parallel the molecular profiles of human breast cancer subtypes. While the use of human cell
lines and patient derived xenografts offer the opportunity to study human breast cancer in
vivo, they rely on immunocompromised hosts. The use of genetically engineered mouse mod-
els of cancer offer the advantage and the opportunity to study tumor progression in an
immuno-competent system. As a result, a major focus has been to establish which genetically
engineered mouse models have parallels in human breast cancer. [7]. Expanding upon these
findings with additional tumor models and samples, numerous reports have documented
mouse and human counterparts at the level of gene expression [8–12]. In addition, copy num-
ber variation at the chromosome [13]and gene level [14]has been predicted from expression
data and examined similarity to human breast cancer. The gene level CNV predictions demon-
strated that chromosomal alterations were associated with histological subtypes[14]. With
gene expression similarities to human breast cancer, a critical need remains to address how the
tumor histology of mouse mammary tumors is related to gene expression programs.
Gene signatures and histological subtypes of breast cancer
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As seen in human breast cancer, a large number of histological subtypes have been observed
for mouse mammary tumors [15]. This includes glandular, acinar, cribriform, papillary, solid,
squamous, fibroadenoma, adenomyoepithelioma, adenosquamous, microacinar, adenocarci-
noma, comedoadenocarcinoma, and medullary [8, 15–17]. Prior characterization of mouse
models illustrates a number of mouse models with varied histological subtypes present across
the population of tumors. For example, amongst Myc initiated tumors, epithelial to mesenchy-
mal (EMT)-like, papillary, microacinar, solid, and squamous tumors were observed [18].
Comparison of mouse and human histological subtypes reveals key differences, for example
squamous tumors are not frequently observed in human breast cancer [1, 3]. As such, it is crit-
ical to begin to understand how mouse and human tumor pathologies impact the genomic
relationships between mouse models and human breast cancer.
To address the need to characterize the genomic patterns defining histological subtypes to
allow a mouse / human comparison we have examined a wide spectrum of mouse model
tumors. In previous work we observed that unsupervised hierarchical clustering of Myc initi-
ated tumors resulted in subclasses that correlated with their histology [19]. Further, even in the
presence of loss of the activator E2F transcription factors, clustering arranged tumors accord-
ing to histology, rather than genotype[20]. This suggested that there are unique gene expres-
sion components inherent to histological subtypes apart from the initiating oncogenic events.
Using gene expression data from histologically annotated mouse mammary tumors initiated
by different oncogenic events, we have developed gene expression signatures that define
tumors with squamous or adenosquamous, EMT-like, microacinar, solid, papillary, or adeno-
myoepithelial tumor histology. Applying these signatures to our published database [9] of
mouse mammary tumors we scored mouse tumors for histology, tested which cell signaling
pathways tightly correlate with tumor histology, and investigated signature relationships to
human breast cancer. Together, this data demonstrates robust signatures that can be used to
predict tumor histology and further our understanding of human breast cancer heterogeneity.
Results
Generation and validation of histology gene expression signatures
To build a gene expression signature that could identify specific histological types of tumors,
we utilized publicly available gene expression data that was annotated for mammary tumor
histology for each sample analyzed on array. For each tumor type that we built signatures for,
histology is described in Table 1 according to descriptions from expert pathologists [15, 21].
Using significance analysis of microarrays(SAM), we identified genes uniquely and consis-
tently differentially expressed in a specific tumor histology in a training dataset. For example,
we utilized histological classifications of tumors from our previous study of the MMTV-PyMT
mouse model where squamous, microacinar, and papillary tumors arise [16](Fig 1A). Using
SAM, we filtered out genotype differences to identify genes consistently differentially regulated
and intrinsic to the squamous identity (Fig 1B). Focusing only on the genes detected in all four
comparisons, we identified 184 genes upregulated in squamous tumors. We did not detect any
genes that were consistently downregulated in this comparison. We tested the performance of
these genes on the training data using unsupervised hierarchical clustering. As expected, this
separated adenosquamous tumors from papillary and microacinar tumors regardless of E2F
status (Fig 1C).
To validate these genes, we then tested performance on a separate dataset of histologically
annotated tumors (MMTV-Myc tumors). Unsupervised hierarchical clustering separated
Myc-induced squamous tumors from non-squamous tumors (Fig 1D) and importantly gene
set enrichment analysis (GSEA) showed that Myc induced squamous tumors were significantly
Gene signatures and histological subtypes of breast cancer
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enriched for upregulation of the squamous signature genes derived from the MMTV-PyMT
tumor dataset (Fig 1E, Normalized Enrichment Score or NES = 1.48, nominal p-value = 0.0,
FDR q-value = 0.029, fwer p-value = 0.016). This illustrated the squamous signature genes as
robust and valid with the ability to properly classify squamous tumors in another gene expres-
sion dataset and in tumors initiated by a different oncogene.
Using a very similar approach, we generated gene expression signatures for EMT-like
tumors (S1 Fig), microacinar tumors (S2 Fig), papillary tumors (S3 Fig), solid tumors(S4 Fig),
and tumors with adenomyoepithelial(S5 Fig) content. In each case, potential signature genes
were identified using SAM (q-value 5%) doing multiple comparisons between the target
tumor histology and other tumor types in the dataset. Unsupervised hierarchical clustering
and GSEA was used on a separate histologically annotated dataset to validate the signature.
As additional validation of our signatures, we examined individual genes for prior associa-
tion with histological types in the literature. As shown in Table 2, several of the squamous sig-
nature genes have been shown to be markers for squamous tumors and keratinocytes.
Similarly, many of the traditional markers (such as Zeb1, vimentin, E-Cadherin) of EMT were
captured in our signatures. In addition, genes from the papillary and adenomyoepithelial sig-
natures also had been observed as markers of these histologies. Together, the ability to detect
known histological subtypes across datasets and mouse models as well as the historical use of
several individual genes depicts these signatures as robust classifiers of mouse mammary
tumor histology. Importantly, each of the histological signatures is provided as a supplemental
file (S1 File) in GSEA “.gmt” format as a predictive resource.
Applying histology gene expression signatures across mouse mammary
tumor models
To test our gene expression signatures in mouse mammary tumors, we utilized two published
mouse mammary tumor model databases [9, 22]. To identify the most likely histology of each
tumor in the dataset, we utilized single sample GSEA (ssGSEA) and ordered tumors according
to their highest scoring signature. With this approach, we observed tumors with robust expres-
sion of signature genes for each histology (Fig 2 and S6 Fig). In addition, there were also
tumors that did not show strong expression patterns for a particular histology signature, likely
indicating a different histology without a predictor.
Table 1. Cellular organization and features associated with tumor histological types.
Histology Description
Squamous Squamous cells with keratin pearls mixed throughout. Lacking of any glandular
pattern. Cells have dense nuclei with coarse chromatin.
EMT Composed of spindle like cells in bundle and sheet form. Cells have large,
pleomorphic nuclei with open chromatin and pale polar cytoplasm.
Microacinar Small luminal spaces separate glandular structures. Acini lined with neoplastic
cuboidal and basal myoepithelial cells. Cells have large nucleoli.
Papillary Epithelial projections maintaining some glandular structure throughout. Cuboidal or
columnar shaped epithelial cells arranged in sheets, extend from a fibrous cell
layer. Cells have oval shaped nuclei.
Solid Epithelial cells arranged in solid sheets, and lacking any glandular structure. Nuclei
tend to be small and oval shaped, but can be pleomorphic.
Adenomyoepithelioma Mixture of gland-like structures surrounded by myoepithelium. Polyploid lesions
are well defined. Uniform Acinar structures are coated with luminal type of
epithelium, which are also uniform.
https://doi.org/10.1371/journal.pgen.1007135.t001
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With application of these signatures, we see evidence for profound histological heterogene-
ity both across and within mouse models. For example, Myc, PyMT, Wnt, Large T, and p53
lines had tumors with a squamous prediction. Indeed, no histological prediction was repre-
sented by a single mouse model and most mouse models (as categorized by the driver event)
showed histological heterogeneity. For example, Wnt, Met, and Myc induced tumor models
presented tumors with high scores for each of the other histological subtypes, consistent with
reports of histological heterogeneity in these models [18, 23, 24].
Alternatively, other models had a preponderance of a particular histological outcome. This
is best represented by the Wap-Int3 and Notch induced tumors which were predominantly
enriched for the papillary signature. Another model, H-Ras initiated tumors favored microaci-
nar and solid nodular outcomes. Interestingly, models featuring inducible expression of an
oncogene, showed elevation of the EMT signature in the recurrent tumors(S7 Fig); consistent
with prior reports [25, 26]. Finally, predictions organized into figures for each individual
mouse model are provided as additional material (S2–S28 Files).
As an additional test of the validity and capability of our signatures, we itemized tumors
that had been individually annotated for a particular histology by a pathologist (see blue bars
above heatmap, Fig 2). Overall, the pathologist based classification of individual tumors and
the classification predicted by the expression signatures demonstrated a high degree of agree-
ment. In addition to this, we cross-referenced the literature to determine whether any of the
predicted histologies for a given mouse mammary tumor had been observed in reports for that
model. As shown in Table 3, many of the predicted histological match reports for tumors from
individual mouse models. Finally, MMTV-Myc tumors with mixed histology (multiple
Fig 1. Generation and validation of mouse mammary squamous tumor signature. (A)Tumor histologies observed in a study MMTV-PyMT tumors[54].
(B) Venn diagram illustrating the number of genes identified in each comparison using significance analysis of microarrays, 184 genes were commonly
identified and proposed as signature genes. (C) Heatmap representation of unsupervised hierarchical clustering of MMTV-PyMT tumors limited to squamous
signature genes shows performance of the signature on the training dataset. Levels of RMA normalized median centered expression values are shown
according the colorbar. Genes expression data is deposited on GEO datasets GSE104397. (D) Heatmap representation of unsupervised hierarchical
clustering of MMTV-Myc tumors limited to squamous signature genes shows performance of the signature on the validation dataset. Levels of RMA
normalized median centered expression values are shown according the colorbar. (E) Gene set enrichment analysis testing for enrichment of the proposed
squamous signature genes shows significant enrichment in MMTV-Myc squamous tumors (normalized enrichment score, NES = 1.48, nominal p-value = 0.0,
FDR q-value = 0.029).
https://doi.org/10.1371/journal.pgen.1007135.g001
Table 2. Known histological associations for single genes within signatures.
Signature Gene(s) Ref
Squamous Bmp2, Bmp4, Bmp7 [66, 67]
Squamous Krt1, Krt10, Krt14, Krt16, K17 [68–71]
Squamous Wnt6 [72]
Squamous Sprr1b [73]
EMT Up Vegfc [74]
EMT Up Zeb1 [75]
EMT Up Vim [75]
EMT Down Epcam [76]
EMT Down Cldn1, Cldn3 [77, 78]
EMT Down Cdh1 [75, 79]
Papillary Krt19 [80]
Papillary Hey2 [81]
Papillary Muc 15 [82]
Adenomyoepithelial Tnni2 [83]
https://doi.org/10.1371/journal.pgen.1007135.t002
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histological components within a single tumor) were noted to have strong scores for individual
histology signatures. Thus, we examined matched H&E sections and find that in 89% of sam-
ples, the predicted histology was present in at least half the section and 100% concordance
where the predicted histology was present in some part of the sample (S8 Fig). Thus, these sig-
natures demonstrate the ability to resolve intra-tumor heterogeneity by identifying the domi-
nant histological component of the tumor being transcriptomically profiled. Importantly, all
scores for tumors in each dataset are provided for download (S29 File).
Fig 2. Testing mouse mammary tumor histology signatures across a gene expression database of mouse mammary tumor models.
Above the heatmap black bars depict the position of each tumor from a given major oncogenic model of mammary tumorigenesis. Samples
marked with red bars are mouse cells lines that are labeled according to their differentiation as being mesenchymal, epithelial, or basal. Next, blue
bars depict available histological annotations for individual tumors in the dataset. Beside the middle heatmap, the black bars indicate the position
of signature genes row by row. The middle heatmap displays the RMA-normalized median centered expression level of each gene in a given
signature across samples; expression levels are depicted by the color bar on the right hand side. The bottom heatmap displays enrichment scores
for each sample and signature from single sample gene set enrichment analysis (ssGSEA). Each sample was tested for the signature (consisting
of ‘up’ genes) that it scored maximum for. Samples were grouped according to their highest scoring signature and all samples and heatmaps were
sorted high to low within each ssGSEA identified group.
https://doi.org/10.1371/journal.pgen.1007135.g002
Table 3. Gene expression signatures of histology predict known histological associations in mouse
models.
Signature Model Ref
Squamous MMTV-Myc [18, 35]
Squamous DMBA [84]
Squamous PIK3Ca [85]
Squamous MMTV-PyMT [46, 54, 86]
Squamous MMTV-Met [24]
Squamous Brg1 +/- [87]
Squamous MMTV-Wnt [23, 88]
Squamous BRCA & p53 mutant [89, 90]
Squamous ETV6-NTRK3 [91]
EMT MMTV-Met [79]
EMT P53 null [33]
EMT Inducible NEU [92]
EMT MTB-IGFIR [26]
EMT Cell type [93]
EMT MMTV-Myc, MTB-Tom [18, 25, 35, 94]
EMT DMBA [84]
EMT TAG [94]
Microacinar MMTV-PyMT [54, 95]
Microacinar MMTV-Wnt [29, 96]
Microacinar MMTV-Myc, MTB-Tom [18, 25, 35]
Microacinar APC cKO [97]
Solid MMTV-Neu, MMTV-NIC [29, 98, 99]
Solid MMTV-PyMT [17, 86, 99]
Papillary Wap-Int3 [100]
Papillary MMTV-PyMT [46, 54, 86, 101]
Papillary MMTV-Wnt [23]
Adenomyoepithelial PIK3Ca [85]
Adenomyoepithelial BRCA & p53 mutant [90]
https://doi.org/10.1371/journal.pgen.1007135.t003
Gene signatures and histological subtypes of breast cancer
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Associations between histology signatures and mammary cell
differentiation
With our large dataset and robust performance of the histology signatures, we aimed to test for
relationships between tumor histology and other features of mammary gland differentiation.
To enable these comparisons, we used the histological classifications made by ssGSEA for each
tumor and used standard GSEA to test for enrichment of other signatures in a comparison of
predicted tumor histological subtypes (S30 File).
We noted prominent associations between histological classes of tumors and signatures for
mammary cell types. As shown in Fig 3A, squamous, EMT, and tumors with high adenomyoe-
pithelial content showed high expression signatures for mammary stem cells and mammary
basal cells. Amongst these, EMT tumors displayed features most concordant with mammary
stem cells. Squamous tumors showed the highest expression of the mammary basal signatures
and had gene expression features (S9A and S9B Fig) that suggests these tumors are further
along the differentiation spectrum than EMT tumors but not as differentiated as other histol-
ogy types (S9C and S9D Fig). Papillary tumors were more luminal progenitor-like, showing
moderate expression of both mammary stem cell and luminal progenitor cell signatures.
Finally, the microacinar and solid tumors showed gene expression patterns consistent with
those found in mature luminal cells(Fig 3A).
We also evaluated the relationships of signatures of breast cancer subtype (Fig 3B)[5]. Squa-
mous tumors had highest expression of signatures for basal subtypes of breast cancer. As
expected, EMT tumors showed high expression of a signature for claudin low subtypes and
showed less luminal or basal-like features. Papillary and tumors with high predicted adeno-
myoepithelial content showed more moderate expression of all signatures for subtype; while
microacinar and solid tumor types had high expression of signatures for luminal breast cancer.
As a whole, this suggests a range of differentiation states across histological types.
Associations between histology and tumor features
We next tested for relationships between histologies and specific features with tumor progres-
sion (Fig 3C). Consistent with prior studies[27], EMT tumors showed high expression of the
hallmark angiogenesis signature. In addition, microacinar and solid tumors exhibit low
expression of this signature. In addition to angiogenesis, it was interesting to note differential
expression of breast cancer metastasis signatures in these mouse mammary tumor types. The
‘Vantveer Breast Cancer Metastasis Up’ signature was high in microacinar tumors and low in
EMT tumors, while EMT tumor showed expression of other metastasis signatures. In addition,
squamous tumors showed lower expression of metastasis signatures. Together, this suggests
differences in metastatic capacity and mechanism for individual tumor histologies.
Associations between histology and molecular features
In addition to phenotypic features, we also tested for key molecular aspects of each tumor his-
tology. In many cases, the histology signatures themselves provide insight into key molecular
features, as key signaling molecules were present in several of the signatures. Fig 4A, shows ele-
vation of several pathways consistent with the relationships already detected. For example,
Hedgehog and Wnt signaling in squamous tumors[28–31]. In addition, several pathways are
shared between histology types. For example, EMT and squamous tumors share high expres-
sion of Kras signatures. Microacinar and solid tumors share Erbb2 signature expression,
AKT1 signaling via MTOR signature expression, and very low expression of Vhl targets.
Examining transcription factors (Fig 4B), a number of key relationships are predicted. Some
Gene signatures and histological subtypes of breast cancer
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are known markers, such as TP63 in squamous and Zeb1, Yap, and Ets transcription factors in
EMT tumors are noted. However, unexpected relationships were also present such as Esr1 in
microacinar tumors. Despite similarities luminal features, it is interesting to note that the E2F1
signatures distinguishes solid tumors and microacinar tumors. Signature genesets were also
tested for overrepresentation in curated pathway databases, offering predictions of additional
pathways of interest for each type of tumor histology (S10 Fig and S11 Fig)
Examining potential miRNAs with GSEA (Fig 4C), suggests tumor types where miRNAs
may be actively expressed or lost. For example, mir-202, mir-17-3p, mir-517 targets are highly
expressed in EMT tumors and lowly expressed in the more luminal tumors. Mir-486 was also
interesting as its targets showed low expression almost exclusive to microacinar and EMT
tumors. Similarly, mir-133A showed evidence for repression in papillary tumors. Taken
together, these data suggest a number of key molecular features from pathways, transcription
factors, miRNAs for each tumor histology.
Associations between mouse histology signatures and human breast
cancer
Given high expression of human breast cancer signatures in certain histologies (ie- luminal
signatures in microacinar),we tested whether any of the mouse tumor histology signatures
were enriched in subtypes of human breast cancer using the Metabric dataset[32]. As shown in
Fig 5A, a portion of the squamous signature was highly expressed in basal tumors. This sug-
gests that mouse mammary squamous tumors are basal-like, but human basal tumors are not
known to be squamous. However, human basal tumors and mouse squamous tumors shared
similarly high expression of well-studied pathway ligands within the squamous signature
(shared high expression of Wnt10a, Wnt6, Bmp2, Bmp7, and Jag2). Moreover, testing the 45
common highly expressed genes for overrepresentation in pathway signatures indicates possi-
ble shared activation of Hedgehog, Wnt, and Bmp pathways in mouse squamous tumors and
human basal breast cancer (S12 Fig). Similarly, a subset of the genes that are highly expressed
in microacinar tumors were highly expressed in luminal subtypes. Amongst these microacinar
genes, many have previously been associated with luminal breast cancer and are also amongst
genes that define mature luminal cells (S13 Fig). Finally, both genesets (up and down) that
define EMT tumors were significantly expressed in claudin low tumors S14A and S14B Fig).
This result is consistent with numerous reports that mouse EMT tumors are molecularly simi-
lar to claudin low tumors[7, 8, 12, 26, 33]. Together, these data further define appropriate
mouse counterparts for study of human breast cancer.
With high expression of signature genes in certain subtypes of human breast cancer, it was
important to test whether these signatures displayed predictive capacity of clinical events
across human breast cancer patients. As shown by Kaplan-Meier analysis, high expression of
the EMT and adenomyoepithelial signatures are associated with acceleration of tumor relapse
in basal-like breast cancer (Fig 5B and 5C respectively). Adenomyoepithelial signatures were
also associated with relapse and earlier onset of distant metastasis in Lum B breast cancer (Fig
5D, S14C Fig respectively), while having high expression of the solid signature was protective
in luminal B (Fig 5E). Finally, high expression of the papillary signature genes were associated
Fig 3. ssGSEA testing of signatures suggests key phenotypic traits of histological tumor classes. (A) Boxplot of enrichment
scores pertaining to normal mammary cell differentiation states. (B) Boxplot of enrichment scores pertaining to molecular subtypes of
breast cancer, the gene-sets used for this analysis were derived from a prior publication[5]. (C) Boxplot of enrichment scores pertaining
to key features of tumor progression and metastasis. * = Significant Enrichment detected in standard GSEA(nominal p-value<0.05); see
additional S30 File for additional details and statistics.
https://doi.org/10.1371/journal.pgen.1007135.g003
Gene signatures and histological subtypes of breast cancer
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with accelerated progression to distant metastasis in Her-2 enriched breast cancer (S14D Fig).
Together, these results suggest potential mouse tumor types for investigating these human
counterparts and prognostic features.
Associations between mouse histology signatures and human cancer
types
Since some of the histology types observed in mouse mammary tumors are often found in
other human cancers (ie- squamous lung tumors, papillary thyroid tumors), we sought to test
whether the mouse signatures were enriched in other human cancer types. We utilized public
gene expression data from the gene expression omnibus and mediated batch effects according
to established protocol[9]. Using unsupervised hierarchical clustering arranged many of the
tumors with squamous histology across lung, oral, melanoma, and esophageal cancer types
into the same cluster with high expression of our murine squamous signature (Fig 6A, green
cluster) and GSEA testing showed significant enrichment in these tumors (Fig 6B). While the
mouse mammary tumor squamous signature extended to other human cancers, the murine
papillary signature was not highly expressed in human papillary tumors. The other murine sig-
nature with enrichment in human cancers were the EMT signatures that showed concordant
expression in a subset of melanoma and metastatic melanoma tumors (Fig 6A, blue cluster).
As expected, GSEA showed significant enrichment in these tumors (Fig 6C, S15 Fig).
Given that we have itemized many similarities between gene expression profiles of mouse
human tumors across cancer types, we tested for unifying features at the level of transcrip-
tomic indicators of pathway activity and differentiation. The concise summary is shown in Fig
7 and more detailed results are available in S16–S18 Figs. Collectively, we observed that murine
mammary tumors from the EMT histopathology is similar to human tumors from claudin low
breast and melanoma. This includes having gene expression features similar to those found in
stem cells and having Kras pathway activity. Mouse and human squamous tumors share
enrichment of basal-cell genes and HRas pathway activity, and while similar pathways are
active in human basal breast tumors, basal-like breast tumors were enriched for upregulation
of luminal progenitor cell genes. We were unable to find human counterparts for the murine
papillary tumors in our analyses. For mouse mammary microacinar and solid tumors, luminal
features were observed, and like human luminal tumors, enrichment for luminal cell signa-
tures were detected; complete with high expression of ER-target genes. Taken as a whole, these
observations suggest that many features of murine tumor histologies are conserved from
mouse to human and across several different cancer types.
Discussion
In this study, we generated and validated signatures for specific histologies that are observed in
mouse mammary tumor models. Both training and validation sets utilized prior histological
annotations from expert pathologists from a number of studies. With our signature generation
and validation approach (Fig 1, S1–S5 Figs), we show that features of tumor histology span
oncogenic mouse models of cancer and human cancers (Figs 5–7). As shown in Fig 2 and
Table 3, these signatures were predictive of known historical observations for tumor models in
our dataset. Thus, we believe these signatures to be a valuable resource tool and have provided
Fig 4. ssGSEA testing of signatures shows key molecular traits histological tumor classes. (A) Boxplot of enrichment scores
pertaining to key cell signaling pathways. (B) Boxplot of enrichment scores pertaining to gene sets for gene targets of specific transcription
factors. (C) Boxplot of enrichment scores pertaining to gene sets for gene targets of specific miRNAs. * = Significant Enrichment detected
in standard GSEA (nominal p-value<0.05); see additional S30 File for additional details and statistics.
https://doi.org/10.1371/journal.pgen.1007135.g004
Gene signatures and histological subtypes of breast cancer
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our signatures in gene set enrichment analysis format. With a robust capacity to identify
tumor histology types, we used this platform to investigate and predict molecular features of
each tumor histology all the way from broad features such as differentiation, to specific molec-
ular aspects such as pathway, transcription factor, and miRNA utilization.
Based on prior studies, relationships between the mouse EMT signature and claudin low
tumors [12, 33–35] were expected. In addition, recent reports have highlighted cases of mela-
noma that classify as claudin-low[27, 36, 37]. Unlike the relationship between human basal
breast cancer and mouse squamous tumors, this relationship is likely due to similar histologies;
as breast and melanoma claudin low tumors, like EMT tumors, have been reported to contain
spindle-shaped cells[2]. Importantly, evidence of stem-cell like properties and Kras activation
was identified in each of these cancer types. Activating mutations in Kras have been observed
in mouse EMT[18, 35, 38], however in human breast cancer, the prevalence is somewhat low,
as COSMIC[39] reports 80 instances that lack intrinsic subtype information (with the excep-
tion of MDA-MB-231 cells that are claudin low). In the case of melanoma, it seems likely mea-
sures for Kras activity stem from downstream activating mutations in Braf, which are
common to melanomas (COSMIC reports 44% of melanomas with Braf mutations).Together,
these data suggest events affiliated with the Kras pathway are important to the EMT / claudin
low outcome.
We also detected relationships between squamous tumors and human basal breast cancer
that seemed to stem from shared activity of multiple pathways. These shared pathways, such as
Hras and hedgehog signaling, seem to come from activation events outside of mutations of
those genes as both COSMIC and C-Bio-Portal illustrate a low incidence for DNA events on
these genes. Although, as reported by TCGA, 32% of basal-like breast cancers harbor amplifi-
cations of Kras[40]; suggesting the Hras signature maybe measuring Kras activity in these
tumors. Regardless, the shared activation of key pathways supports the use of squamous
tumors as a tool for investigating human basal breast cancer at the pathway level.
Mouse microacinar tumors showed gene expression traits that define luminal breast can-
cers. At the pathway level, the relationships between mouse microacinar and human luminal
breast cancers is still somewhat perplexing. While both the mouse and human tumors show
strong expression of mature luminal cell differentiation signatures and activation of several
pathways, mouse microacinar tumors also show activation of Erbb2 signaling, which is tradi-
tionally associated with the Her-2 enriched subtype of breast cancer. Furthermore, the microa-
cinar tumors showed high expression of signatures for estrogen receptor signaling. Yet, mouse
mammary tumors are notoriously ER-negative by IHC. Indeed, this does draw comparisons to
the human setting where Her-2 negative tumors still classify as Her-2 enriched in intrinsic pro-
filing despite the IHC diagnosis as Her-2 negative[41]. This might indicate that similarities to
Fig 5. Histology signature analysis across intrinsic subtypes of breast cancer. (A)Heatmap depicting expression of mouse
mammary tumor derived histology signatures in the METABRIC dataset featuring each intrinsic subtype of breast cancer. Genes are
illustrated my median centered, log2 normalized expression level. Samples were clustered within each intrinsic and then genes were
clustered within each signature across tumors. (B) Analysis of the EMT signature (highly expressed in EMT) genes in basal-like human
breast cancers shows that high expression of this signature is significantly associated with earlier incidence of tumor relapse.
pval = 0.0108, HR = 2.05, N = 142. (C) Analysis of the adenomyoepithelial signature genes in basal-like human breast cancers shows
that high expression of this signature is significantly associated with earlier incidence of tumor relapse. pval = 7e−04, HR = 2.63, N = 142.
(D) Analysis of the adenomyoepithelial signature genes in luminal B human breast cancers shows that high expression of this signature is
significantly associated with earlier incidence of tumor relapse. pval = 7e−04, HR = 2.63, N = 447. (E) Analysis of the solid signature
genes (highly expressed in solid tumors) in luminal B human breast cancers shows that high expression of this signature is significantly
associated with delayed incidence of tumor relapse. pval = 0.0159, HR = 0.721, N = 447. Kaplan-Meier analysis was done using the
http://geneanalytics.duhs.duke.edu/Surv_sig.html tool. Samples were assigned to groups based on being above or below the median
population value.
https://doi.org/10.1371/journal.pgen.1007135.g005
Gene signatures and histological subtypes of breast cancer
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007135 January 18, 2018 15 / 34
Gene signatures and histological subtypes of breast cancer
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007135 January 18, 2018 16 / 34
luminal breast cancer are achieved by expression of estrogen receptor target genes by a mecha-
nism other than estrogen receptor itself.
Interestingly, several of our mouse histology gene signatures were prognostic in specific
intrinsic subtypes of human breast cancer. For example, luminal B tumors with high expres-
sion of the solid tumor signature displayed prolonged times to relapse. This finding is particu-
larly of note in light of the recent finding that HER2+ tumors with luminal B gene expression
profiles benefitted significantly from trastuzumab[42]; similarly, we note elevation of a Her-2
(Erbb2) signature in murine solid tumors that also have luminal expression profiles (Fig 4A).
However, our solid signature was not predictive of prognosis in Her-2 enriched tumors,
Fig 6. Histology signature analysis across human cancers. (A)Unsupervised hierarchical clustering of human tumors on the basis of
mouse mammary tumor histology signatures. Above the heatmap, blue depict the position of individual tumors annotated by cancer type
in the dendrogram above and heatmap below. The red bars provide histological and additional information for each sample. The black
bars beside the heatmap annotate the position of each signature gene in the heatmap. The green cluster highlights the cluster featuring
the majority of squamous tumors while the blue cluster in the dendrogram highlights a mesenchymal cluster largely composed of
melanoma. (B) Geneset enrichment analysis shows significant enrichment of mouse derived squamous histology in tumors from the
green squamous cluster. NES = 1.92, nominal p-value 0.0, FDR q-value = 0.003 (C) Geneset enrichment analysis shows significant
enrichment for high expression expression of mouse derived EMT histology signature (genes highly expressed expressed in EMT
tumors) in samples belonging to the blue cluster in A. NES = 1.93, nominal p-value 0.0, FDR q-value = 6.97 E -4.
https://doi.org/10.1371/journal.pgen.1007135.g006
Fig 7. A summary of the detected similarities between mouse mammary tumors and human tumors across cancer types. Mouse mammary
tumor types and human cancers and are ordered to reflect similarities in differentiation and pathway activation. The far left window depicts mouse
mammary EMT tumor models that parallel human claudin low breast and melanoma. As illustrated, these tumors show Kras pathway activity and
stem-cell like gene expression profiles (as marked by pink bars). The middle window highlights the murine models that feature squamous tumors;
these tumors show similarities to human pan-cancer squamous tumors for basal cell like gene expression (as marked by red bars) and to both
human squamous cancers and basal-like breast cancers for Hras pathway activity. As indicated by green bars, human basal tumors had luminal
progenitor-like gene expression profiles. The far right window highlights murine solid tumor models and microacinar models, which show more
luminal-like features (marked by blue bars). Like human luminal tumors, these murine models feature high expression of ER-target genes and tend
to show gene expression patterns that suggest they are more differentiated than their other species-specific tumor types.
https://doi.org/10.1371/journal.pgen.1007135.g007
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suggesting the criticality of other pathways differentially regulated between luminal and Her-2
enriched tumors. High levels of EMT and adenomyopithelial signatures were associated with
accelerated relapse in basal-like breast cancers (likely identifying basal-like tumors with clau-
din-low like properties). Indeed, relapse following chemotherapy is common in these tumors
[43] and other work has shown an association of EMT phenotypes with chemo-resistance, in
part due to lower rates of proliferation and apoptosis[44, 45]. Taken together, these findings
are of particular significance because they may specify high risk patients where alternative
therapies may be necessary. In addition, these signatures may suggest appropriate mouse mod-
els for testing new therapeutic strategies.
The fact that the same histological fates are often achieved despite differences in oncogenic
events, genetic background, and promoter ultimately questions the mechanism(s) for develop-
ment of a particular tumor histology. Examination of mammary cell differentiation signatures
across tumors revealed unique differentiation states within each tumor histology. Indeed, it is
tempting to infer that this indicates the cell of origin leading to tumor initiation and that this
cell of origin ultimately drives histological outcome. Indeed, work using the PyMT model sug-
gests that cell of origin plays a role in histological outcome [46]. Yet, more recent work coun-
ters that while cell of origin still might be a factor, the initiating oncogenic mutation plays a
large role in the histological outcome[47].
In light of these findings[47, 48] and our study, one might envision that the particular com-
bination of pathways that are activated could commit cells into a specific differentiation state.
Alternatively, this could also cause selective outgrowth of specific populations of cells. Ulti-
mately either case would result in tumors forming a particular histology. In support of this,
previous work using an inducible Myc mouse model showed that after Myc withdrawal,
tumors regressed, and then recurred with tumors mainly being EMT or squamous with acti-
vating mutations in Kras [25]. In part, activation of Kras was thus associated with development
of these characteristic tumor pathologies. In addition, we and others have observed Kras acti-
vation in both of these histological types in other models [35, 49, 50]. Indeed, our work pre-
sented here might provide predictions as to which differentiation state of cells and which
pathways drive the formation of particular histologies.
While our method provides robust classification of tumors in our large dataset, there is one
important application guideline we wish to highlight. Due to gene centering techniques that
are often employed with normalization of gene expression data, predicting tumor histology
should be done in settings with adequate tumor heterogeneity or done using methods that
adjust for skewed pathological data. In cases where heterogeneity across the dataset is low, we
recommend batch adjusting[51, 52] to combine datasets of interest with large datasets such as
our own[9] or others [7, 10] prior to employing gene signatures. In addition, we wish to refer
to the work of Zhao et al which describes in great detail the issues surrounding gene centering
and classification of homogenous cohorts while providing alternative approaches for solving
such issues[53]. Indeed, the technicalities of gene centering on skewed molecular datasets
highlight the necessity of conventional classification methods such as IHC and pathology of
H&E stained sections to enable proper data handling.
Finally, though traditional tumor classification methods are essential, the gene-signature
based classification method here offers several key advantages. First, intra-tumor heterogeneity
presents challenges for accurate interpretation of the data that cannot always be addressed by
conventional methods. Illustrating this, we examined a large number of tumors presenting
mixed tumor histology where the portion of the tumors analyzed on microarray displayed a
gene expression profile representing a major histological class. Importantly, the histology pre-
dicted by our gene expression signatures were concordant with the major component present
in the associated histological section. Therefore, these signatures represent an important tool
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for resolving mixed cases and ensuring molecular profiles match the expected histology from
H&E. Another advantage over conventional methods is the reduced variance in the clinical
classification of tumors and classifying cases where histology might be misleading. This is
demonstrated by Her-2 enriched Her-2-IHC negative tumors in human breast cancer [41] and
ER-target gene enrichment in ER-IHC-negative microacinar tumors from mouse mammary
tumor models. Finally, we demonstrate the ability of gene signatures to tie tumor cell pheno-
types and functions to supporting pathways that represent therapeutic targets beyond the
capacity of IHC. It is our hope that this work’s correlation of gene expression signatures to spe-
cific cell biology in the form of tumor histopathologies may provide useful inroads to under-
standing tumor subtype, tumor progression, and for identifying specific therapeutic strategies
aimed at the biological processes upon which the tumor cells depend.
Methods
Ethics statement
Previously published gene expression data were derived from mouse and human tumors and
done in accordance to the ethics statements as reported in their respective publications.
Microarray data
Details for assembling the mouse mammary tumor model databases can found [9, 22]. For the
squamous signature, the training data was derived from squamous and non-squamous
MMTV-PyMT tumors; this data is deposited on GEO Datasets GSE104397 [54]. All animal
work has been conducted according to national and institutional guidelines. These tumors
were prepared by isolation of RNA samples from flash frozen tumors using the Qiagen RNeasy
kit after roto-stator homogenization. RNA was submitted to the Michigan State University
Genomics Core facility for gene expression analysis using Mouse 430A 2.0 Affymetrix arrays.
The validation set for the squamous signature was from MMTV-Myc tumors found under
GSE30805 and GSE15904[8]. The training dataset for generation of the EMT signature is pub-
lished, GSE30805 and GSE15904 [8]. The validation dataset for the EMT signature can be
found GSE41601[12]. Generation of the microacinar signature was done by dividing the pub-
lished dataset[8] into training and validation sets with random sample selection. The training
dataset for generation of the papillary signature is published, GSE30805 and GSE15904 [8].
The validation sets for the papillary signature were from Array Express E-MEXP-3663 [55]
and gene expression omnibus GSE20614[56]; batch effects between datasets were mediated
using combat[52]. The solid tumor signature was generated using the training dataset
GSE41601[12] and validated using GSE73073[57]. Finally the signature for adenomyoepithe-
lial content was generated using from Array Express E-MEXP-3663 [55], filtered using
GSE69290 [58], and validated on GSE37223[59].
Gene expression data for human squamous and non-squamous tumors was accessed on the
Gene Expression Omnibus under the following accession numbers: GSE10245, GSE10300,
GSE14020, GSE17025, GSE18520, GSE2034, GSE20347, GSE21422, GSE21653, GSE2280,
GSE2603, GSE27155, GSE27678, GSE29044, GSE30219, GSE30784, GSE3292, GSE33630,
GSE3524, GSE35896, GSE37745, GSE39491, GSE39612, GSE43580, GSE45670, GSE4922,
GSE50081, GSE51010, GSE6532, and GSE7553. These datasets were normalized using Affyme-
trix Expression Console. Bayesian Factor Regression Methods (BFRM) [60] was used to com-
bine datasets and remove batch effects.(http://www.stat.duke.edu/research/software/west/
bfrm/download.html).
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Data analysis
Gene expression signatures were derived using significance analysis of microarrays [61] to
detect the genes that were differentially regulated for each tumor histology as illustrated in Fig
1 and S1–S5 Figs. Venn diagrams were generated using online tool available at the following
URL: http://bioinformatics.psb.ugent.be/webtools/Venn/. Unsupervised hierarchical cluster-
ing was done using Cluster 3.0 and Java Tree View. The color scheme for the heatmap and
sample legends were made using Matlab. Gene set enrichment analysis [62] and single sample
gene set enrichment analysis was done by converting our gene expression data and gene lists
to the specified file formats and using these available modules hosted by Gene Pattern[63].
Tumors sorting for Fig 2 was by sorting tumors for the maximum single sample GSEA score
for upregulated genes of any histological type. Pathway and transcription factor overrepresen-
tation analysis was done using Innate-DB[64] and using the Broad Institute’s molecular signa-
tures database ‘investigate gene sets’ web tool[65]. Kaplan-Meier analysis was done using the
http://geneanalytics.duhs.duke.edu/Surv_sig.html tool. Samples were assigned to groups based
on being above or below the median population value.
Supporting information
S1 Fig. Generation and validation of mouse mammary EMT tumor signature. (A)Venn dia-
gram illustrating the number of genes identified in each comparison using significance analy-
sis of microarrays, 185 genes were commonly identified as having higher expression in EMT
tumors and proposed as signature genes. (B) Venn diagram illustrating the number of genes
identified in each comparison using significance analysis of microarrays, 175 genes were com-
monly identified as having lower expression in EMT tumors and proposed as signature genes.
(C)Heatmap representation of unsupervised hierarchical clustering of MMTV-Myc tumors
limited to EMT signature genes shows performance of the signature on the training dataset.
Levels of RMA normalized median centered expression values are shown according the color-
bar. (D) Heatmap representation of unsupervised hierarchical clustering of MMTV-Met
tumors limited to EMT signature genes shows performance of the signature on the validation
dataset. Levels of RMA normalized median centered expression values are shown according
the colorbar. (E) Gene set enrichment analysis testing for enrichment of the proposed upregu-
lated in EMT signature genes shows significant enrichment in MMTV-Met splindoid tumors
(normalized enrichment score, NES = 1.75, nominal p-value = 0.0, FDR q-value = 0.009). (F)
Gene set enrichment analysis testing for enrichment of the proposed downregulated in EMT
signature genes shows significant enrichment for low expression in MMTV-Met splindoid
tumors (normalized enrichment score, NES = -1.66, nominal p-value = 0.006, FDR q-
value = 0.009).
(TIF)
S2 Fig. Generation and validation of mouse mammary microacinar tumor signature. (A)
Venn diagram illustrating the number of genes identified in each comparison using signifi-
cance analysis of microarrays, 45 genes were commonly identified as having higher expression
in MMTV-Myc training set microacinar tumors and proposed as signature genes. (B) Venn
diagram illustrating the number of genes identified in each comparison using significance
analysis of microarrays, 16 genes were commonly identified as having lower expression in
microacinar training set tumors and proposed as signature genes. (C)Heatmap representation
of unsupervised hierarchical clustering of MMTV-Myc tumors limited to microacinar signa-
ture genes shows performance of the signature on the training dataset. Levels of RMA normal-
ized median centered expression values are shown according the colorbar. (D) Heatmap
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representation of unsupervised hierarchical clustering of MMTV-Myc validation set tumors
limited to microacinar signature genes shows performance of the signature on the validation
dataset. Levels of RMA normalized median centered expression values are shown according
the colorbar. (E) Gene set enrichment analysis testing for enrichment of the proposed upregu-
lated in microacinar signature genes shows significant enrichment in MMTV-Myc validation
set microacinar tumors (normalized enrichment score, NES = 1.42, nominal p-value = 0.0,
FDR q-value = 0.02). (F) Gene set enrichment analysis testing for enrichment of the proposed
downregulated in microacinar signature genes shows significant enrichment for low expres-
sion in MMTV-Myc validation set microacinar tumors (normalized enrichment score, NES =
-1.37, nominal p-value = 0.001, FDR q-value = 0.015).
(TIF)
S3 Fig. Generation and validation of mouse mammary papillary tumor signature. (A)Venn
diagram illustrating the number of genes identified in each comparison using significance
analysis of microarrays, 44 genes were commonly identified as having higher expression in
MMTV-Myc training set papillary tumors and proposed as signature genes. (B) Venn diagram
illustrating the number of genes identified in each comparison using significance analysis of
microarrays, 32 genes were commonly identified as having lower expression in papillary train-
ing set tumors and proposed as signature genes. (C)Heatmap representation of unsupervised
hierarchical clustering of MMTV-Myc tumors limited to papillary signature genes shows per-
formance of the signature on the training dataset. Gene filtering of the signature is illustrated
here where genes with great than 5-fold and genes with less than 2-fold downregulation change
were kept for validation testing. Levels of RMA normalized median centered expression values
are shown according the colorbar. (D) Heatmap representation of unsupervised hierarchical
clustering of the validation sets for the papillary signature were from Array Express E-MEXP-
3663 and gene expression omnibus GSE20614 validation set tumors limited to papillary signa-
ture genes shows performance of the signature on the validation dataset. Levels of RMA nor-
malized median centered expression values are shown according the colorbar. (E) Gene set
enrichment analysis testing for enrichment of the proposed upregulated in papillary signature
genes shows significant enrichment in validation set papillary tumors (normalized enrichment
score, NES = 1.44, nominal p-value = 0.02, FDR q-value = 0.52). (F) Gene set enrichment anal-
ysis testing for enrichment of the proposed downregulated in papillary signature genes does
not show significant enrichment for low expression in validation set papillary tumors (normal-
ized enrichment score, NES = 0.72, nominal p-value = 0.84, FDR q-value = 0.77).
(TIF)
S4 Fig. Generation and validation of mouse mammary solid tumor signature. (A)Diagram
illustrating the number of genes identified in each comparison using significance analysis of
microarrays, 20 genes were commonly identified as having higher expression in MMTV-Met
training set solid tumors and proposed as signature genes. (B) Diagram illustrating the number
of genes identified in each comparison using significance analysis of microarrays, 38 genes
were commonly identified as having lower expression in solid MMTV-Met training set tumors
and proposed as signature genes. (C)Heatmap representation of unsupervised hierarchical
clustering of MMTV-Met tumors limited to solid signature genes shows performance of the
signature on the training dataset. Levels of RMA normalized median centered expression val-
ues are shown according the colorbar. (D) Heatmap representation of unsupervised hierarchi-
cal clustering using solid signature genes shows performance of the signature on the validation
dataset. Levels of RMA normalized median centered expression values are shown according
the colorbar. (E) Gene set enrichment analysis testing for enrichment of the proposed upregu-
lated in solid signature genes shows significant enrichment in validation set solid tumors
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(normalized enrichment score, NES = 1.4, nominal p-value = 0.03, FDR q-value = 0.07). (F)
Gene set enrichment analysis testing for enrichment of the proposed downregulated in solid
signature genes shows significant enrichment for low expression in validation set solid tumors
(normalized enrichment score, NES = -1.35, nominal p-value = 0.01, FDR q-value = 0.15).
(TIF)
S5 Fig. Generation and validation of mouse mammary adenomyoepithelial content signa-
ture. (A)Diagram illustrating the number of genes identified in each comparison using signifi-
cance analysis of microarrays, 27 genes were commonly identified as having higher expression
in Array Express E-MEXP-3663 (K14-Cre Brca2 fl/fl p53 fl/fl, Blg-Cre Brca2 fl/fl p53 fl/fl, Pten
+/-, K14-Cre Pten fl/fl, Blg-Cre Pten fl/fl, Blg-Cre Pten fl/fl p53 fl/+, and Blg-Cre Pten fl/fl p53
fl/+) training set adenomyoepithelial tumors and proposed as signature genes. (B) Diagram
illustrating the number of genes identified in each comparison using significance analysis of
microarrays, 51 genes were commonly identified as having lower expression in adenomyoe-
pithelial training set tumors and proposed as signature genes. (C)Heatmap representation of
unsupervised hierarchical clustering of training dataset tumors limited to adenomyoepithelial
signature genes shows performance of the signature on the training dataset. Levels of RMA
normalized median centered expression values are shown according the colorbar. (D) Heat-
map representation of unsupervised hierarchical clustering using adenomyoepithelial signa-
ture genes shows performance of the signature on the first validation dataset. Genes proposed
for the downregulated in adenomyoepithelial tumors did not perform well and were not kept
for further testing. A subset of proposed upregulated adenomyoepithelial genes showed high
expression in adenomyoepithelial tumors and were kept for further validation testing. Levels
of RMA normalized median centered expression values are shown according the colorbar. (E)
Heatmap representation of unsupervised clustering on validation set shows high expression of
proposed adenomyoepithelial genes in adenomyoepithelial cells. (F) Gene set enrichment
analysis testing for enrichment of the proposed upregulated in solid signature genes shows sig-
nificant enrichment in validation set adenomyoepithelial cells (normalized enrichment score,
NES = 1.58, nominal p-value = 0.01, FDR q-value = 0.02).
(TIF)
S6 Fig. Testing mouse tumor histology signatures across mouse models. Above the heatmap
black bars depict the position of each tumor from a given major oncogenic model of mammary
tumorigenesis. Still above the heatmap, blue bars depict available histological annotations for
individual tumors in the dataset. Beside the middle heatmap, the black bars indicate the posi-
tion of signature genes row by row. The middle heatmap displays the RMA-normalized
median centered expression level of each gene in a given signature across samples; expression
levels are depicted by the color bar on the right hand side. The bottom heatmap displays
enrichment scores for each sample and signature from single sample gene set enrichment anal-
ysis (ssGSEA). Each sample was tested for the signature (consisting of ‘up’ genes) that it scored
maximum for. Samples were grouped according to their highest scoring signature and all sam-
ples and heatmaps were sorted high to low within each ssGSEA identified group.
(TIF)
S7 Fig. Testing mouse tumor histology signatures across mouse models of tumor recur-
rence. (A)Recurrent tumors from the IGFIR model show high expression of the “UP IN EMT”
SIGNATURE and low expression of the “DOWN IN EMT” signature suggesting mesenchymal
histology of those tumors. The color bar beside the heatmap depicts ssGSEA enrichment score
values. (B) Recurrent tumors from the MTB-Tom (Inducible Myc) model show high expres-
sion of the “UP IN EMT” SIGNATURE and low expression of the “DOWN IN EMT”
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signature suggesting mesenchymal histology of those tumors. The color bar beside the heat-
map depicts ssGSEA enrichment score values. (C) A subset of tumors from the tet-on Neu
model show high expression of the “UP IN EMT” SIGNATURE and low expression of the
“DOWN IN EMT” signature suggesting mesenchymal histology of those tumors. The color
bar beside the heatmap depicts ssGSEA enrichment score values.
(TIF)
S8 Fig. Gene expression signatures predict dominant components present in mixed tumor
histology. (A) A MMTV-Myc tumor showing EMT, and microacinar histology at 20X magni-
fication. (B) A MMTV-Myc tumor showing microacinar, squamous, and EMT histology at
20X magnification. (C) Gene expression signatures were used to make a histological prediction
for each sample across the previously published dataset [9],including MMTV-Myc tumors of
mixed histology. The pie chart represents the distribution of concordant predictions: whether
the predicted histology was present as either a ‘major’ and ‘minor component’ in the H&E
stained section of the mixed tumors. The ‘present as even split’ slice represents predictions
that were present in the sample, but proportionally equal to one or more other histologies.
Tumor histology was considered a major component if the particular pattern of cellular mor-
phology and organization was present in greater than 50 percent of the H&E stained section.
Minor components were considered if the predicted histology was present as only a small por-
tion (< 50%) of the H&E stained section.
(TIF)
S9 Fig. GSEA comparing murine mammary squamous to other types of mouse mammary
tumors. (A)GSEA comparing squamous tumors to EMT tumors show enrichment for high
expression of the LIM_MAMMARY_STEM_CELL_DN signature in squamous tumors
(NES = 1.78, nominal p-value 0.0009, fdr q-value = 0.29). (B)GSEA comparing squamous
tumors to EMT tumors show enrichment for high expression of the LIM_MAMMARY_LU-
MINAL_PROGENITOR_CELL_UP signature in squamous tumors (NES = 1.68, nominal p-
value 0.02, fdr q-value = 0.40). (C)GSEA comparing squamous tumors to microacinar, solid,
and papillary tumors show enrichment for high expression of the LIM_MAMMARY_STEM_-
CELL_UP signature in squamous tumors (NES = 1.93, nominal p-value 0.005, fdr q-
value = 0.19). (D)GSEA comparing squamous tumors to microacinar, solid, and papillary
tumors show enrichment for high expression of the LIM_MAMMARY_LUMINAL_PRO-
GENITOR_CELL_UP signature in microacinar, solid, and papillary tumors (NES = 1.79,
nominal p-value 0.01, fdr q-value = 1.0).
(TIF)
S10 Fig. Pathway over-representation analysis of histology signature gene lists. (A)Pathway
over-representation of squamous signature genes (Up In Squamous) showing the–log10 of the
p-value; where p = 0.05 is 1.3 for the blue line significance threshold. (B) Pathway over-repre-
sentation of EMT signature genes (Up In EMT) showing the–log10 of the p-value; where
p = 0.05 is 1.3 for the blue line significance threshold. (C) Pathway over-representation of
Microacinar signature genes (Up In Microacinar) showing the–log10 of the p-value; where
p = 0.05 is 1.3 for the blue line significance threshold. (D) Pathway over-representation of Ade-
nomyoepithelial signature genes (Up In Adenomyoepithelial) showing the–log10 of the p-
value; where p = 0.05 is 1.3 for the blue line significance threshold.
(TIF)
S11 Fig. Transcription factor binding site over-representation analysis of histology signa-
ture gene lists. (A)Transcription factor binding site over-representation of squamous signa-
ture genes (Up In Squamous) showing the–log10 of the p-value; where p = 0.05 is 1.3 for the
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blue line significance threshold. (B) Transcription factor binding site over-representation of
EMT signature genes (Up In EMT) showing the–log10 of the p-value; where p = 0.05 is 1.3 for
the blue line significance threshold. (C) Transcription factor binding site over-representation
of microacinar signature genes (Up In Microacinar) showing the–log10 of the p-value; where
p = 0.05 is 1.3 for the blue line significance threshold. (D) Transcription factor binding site
over-representation of papillary signature genes (Up In Papillary) showing the–log10 of the p-
value; where p = 0.05 is 1.3 for the blue line significance threshold. (E) Transcription factor
binding site over-representation of solid signature genes (Up In Solid) showing the–log10 of
the p-value; where p = 0.05 is 1.3 for the blue line significance threshold.
(TIF)
S12 Fig. Signature over-representation analysis of squamous histology signature genes
with high expression in human basal tumors. Pathway over-representation of squamous sig-
nature genes (Up In Squamous) that were highly expressed in human basal breast cancer.
(TIF)
S13 Fig. Signature over-representation analysis of microacinar histology signature genes
with high expression in luminal tumors. (A)Pathway over-representation of microacinar sig-
nature genes (Up In Microacinar) that were highly expressed in human luminal breast cancer.
(B) Gene identity and overlap with signatures of microacinar signature genes that had high
expression in human luminal breast cancer.
(TIF)
S14 Fig. Analysis of mouse histology signatures in human breast cancer. (A) Geneset
enrichment analysis shows significant enrichment of mouse derived EMT histology signature
for genes highly expressed in EMT tumors. NES = 2.3, nominal p-value 0.0, FDR q-value = 0.0
(B) Geneset enrichment analysis shows significant enrichment for low expression of mouse
derived EMT histology signature (genes lowly expressed in EMT tumors). NES = -2.5, nominal
p-value 0.0, FDR q-value = 0.0. (C) Analysis of human breast cancer luminal B tumors for
expression of adenomyoepithelial signature genes reveals high expression is significantly asso-
ciated with earlier distant metastasis events (pval = 0.000405, HR = 1.52, N = 965). Kaplan-
Meier analysis was done using the http://geneanalytics.duhs.duke.edu/Surv_sig.html tool.
Samples were assigned to groups based on being above or below the median population value.
(D) Analysis of human breast cancer Her-2 enriched tumors for expression of papillary signa-
ture genes reveals high expression is significantly associated with earlier distant metastasis
events(pval = 0.0472, HR = 1.5, N = 277). Kaplan-Meier analysis was done using the http://
geneanalytics.duhs.duke.edu/Surv_sig.html tool. Samples were assigned to groups based on
being above or below the median population value.
(TIF)
S15 Fig. GSEA of human tumors organized into the mesenchymal cluster. (A)GSEA of
human mesenchymal cluster tumors (mainly melanoma) shows significant enrichment for
low expression of genes that are down in mouse EMT tumors (NES = -2.17, nominal p-
value = 0.0, FDR q-value = 0.0. (B) GSEA of human mesenchymal cluster tumors (mainly mel-
anoma) does not show significant enrichment for high expression of genes that are upregu-
lated in mammary stem cells.
(TIF)
S16 Fig. GSEA reveals common features in mouse squamous, human basal breast cancer,
and in other human squamous cancers. (A)GSEA plot of the HUPER_BREAST_BASAL_V-
S_LUMINAL_UP signature, which describes non-tumor basal mammary cells compared to
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the luminal cells, is significantly enriched in murine mammary tumors identified as squamous
compared to all other tumors (NES = 2.09, nominal p-value = 0.0002, FDR q-value = 0.11). (B)
GSEA plot of the LIM_MAMMARY_LUMINAL_PROGENITOR_UP signature, which is sig-
nificantly enriched in human basal breast cancer compared to non-basal tumors(NES = 2.18,
nominal p-value = 0.0, FDR q-value = 0.001). (C) GSEA plot of the HUPER_BREAST_BA-
SAL_VS_LUMINAL_UP signature, which is significantly enriched in human cancers orga-
nized into the squamous cluster compared to non-squamous cluster tumors (NES = 1.70,
nominal p-value = 0.0, FDR q-value = 0.14). (D) GSEA plot of the BILD_HRAS_ONCOGEN-
IC_SIGNATURE signature, which is significantly enriched in murine mammary tumors iden-
tified as squamous compared to microacinar, solid, or papillary tumors (NES = 1.91, nominal
p-value = 0.002, FDR q-value = 0.22). (E) GSEA plot of the BILD_HRAS_ONCOGENIC_-
SIGNATURE signature, which is significantly enriched in human basal breast tumors com-
pared to non-basal tumors (NES = 1.97, nominal p-value = 0.004, FDR q-value = 0.01).). (F)
GSEA plot of the BILD_HRAS_ONCOGENIC_SIGNATURE signature, which is significantly
enriched in tumors that organized into the human squamous cluster compared to all other
tumors in the dataset (NES = 1.75, nominal p-value = 0.008, FDR q-value = 0.13).
(TIF)
S17 Fig. GSEA reveals common features in mouse EMT, human claudin low breast cancer,
and in other human cancers. (A)GSEA plot of the LIM_MAMMARY_STEM_CELL_UP sig-
nature, which is significantly enriched in murine mammary tumors identified as EMT com-
pared to microacinar, solid, or papillary tumors (NES = 2.12, nominal p-value = 0.002, FDR q-
value = 0.02). (B) GSEA plot of the LIM_MAMMARY_STEM_CELL_UP signature, which is
significantly enriched in human claudin low breast cancer compared to other breast tumors
(NES = 2.57, nominal p-value = 0.0, FDR q-value = 0.0). (C) GSEA plot of the LIM_MAM-
MARY_STEM_CELL_DOWN signature, which is significantly enriched for low expression in
human cancers organized into the mesenchymal cluster compared to non-squamous cluster
tumors (NES = -2.12, nominal p-value = 0.0, FDR q-value = 0.0). (D) GSEA plot of the HALL-
MARK_KRAS_SIGNALING_UP signature, which is significantly enriched in murine mam-
mary tumors identified as EMT compared to microacinar, solid, or papillary tumors
(NES = 1.79, nominal p-value = 0.001, FDR q-value = 0.03). (E) GSEA plot of the HALL-
MARK_KRAS_SIGNALING_UP signature, which is significantly enriched in human claudin
low breast tumors compared to non-basal tumors (NES = 2.49, nominal p-value = 0.0, FDR q-
value = 0.0). (F) GSEA plot of the HALLMARK_KRAS_SIGNALING_DOWN signature,
which is significantly enriched for low expression in tumors that organized into the human
mesenchymal cluster compared to all other tumors in the dataset (NES = -1.68, nominal p-
value = 0.0, FDR q-value = 0.13).
(TIF)
S18 Fig. GSEA reveals common features in mouse solid and microacinar tumors to human
luminal breast cancer. (A)GSEA plot of the LIM_MAMMARY_LUMINAL_MATURE_UP
signature, which is significantly enriched in murine mammary tumors identified as microaci-
nar to other mouse mammary tumors (NES = 1.63, nominal p-value = 0.02, FDR q-
value = 0.5). (B) GSEA plot of the LIM_MAMMARY_LUMINAL_MATURE_DOWN signa-
ture, which is significantly enriched in for low expression in mouse mammary solid tumors
compared to other mouse mammary tumors (except microacinar, NES = -1.94, nominal p-
value = 0.0, FDR q-value = 0.01). (C) GSEA plot of the LIM_MAMMARY_LUMINAL_MA-
TURE_UP signature, which is significantly enriched in human luminal breast compared to
other subtypes of breast cancer(NES = 2.32, nominal p-value = 0.0, FDR q-value = 2.03 E-4).
(D) GSEA plot of the VANTVEER_BREAST_CANCER_ESR1_UP signature, which is
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significantly enriched in murine mammary tumors identified as microacinar compared to all
other tumors (NES = 2.13, nominal p-value = 0.0, FDR q-value = 0.01). (E) GSEA plot of the
VANTVEER_BREAST_CANCER_ESR1_UP signature, which is significantly enriched in in
mouse mammary solid tumors compared to other mouse mammary tumors (except microaci-
nar, NES = 1.81, nominal p-value = 0.002, FDR q-value = 0.69). (F) GSEA plot of the VANT-
VEER_BREAST_CANCER_ESR1_UP signature, which is significantly enriched in human
luminal breast compared to other subtypes of breast cancer(NES = 2.31, nominal p-
value = 0.0, FDR q-value = 2.03 E-4).
(TIF)
S1 File. Histology signature genes in GSEA format. Individual histology signature genes for-
matted for use in gene set enrichment analysis. This file can be saved as a “.gmt” extension and
then uploaded to GSEA.
(GMT)
S2 File. Heatmap of histology signature scores of Aib1 induced tumors. ssGSEA scores for
histology signatures on Aib1 induced tumors in the context of the published dataset[22].
(PDF)
S3 File. Heatmap of histology signature scores of Apc conditional knockout tumors.
ssGSEA scores for histology signatures on Apc conditional knockout tumors in the context of
the published dataset[9].
(PDF)
S4 File. Heatmap of histology signature scores of MMTV-Atx tumors. ssGSEA scores for
histology signatures on MMTV-Atx tumors in the context of the published dataset[9].
(PDF)
S5 File. Heatmap of histology signature scores of Blg-Stat5 tumors. ssGSEA scores for his-
tology signatures on Blg-Stat5 tumors in the context of the published dataset[9].
(PDF)
S6 File. Heatmap of histology signature scores of Brca1 null tumors. ssGSEA scores for his-
tology signatures on Brca1 null tumors in the context of the published dataset[9].
(PDF)
S7 File. Heatmap of histology signature scores of p53/Brca1 null tumors. ssGSEA scores for
histology signatures on p53/Brca1 null tumors in the context of the published dataset[9].
(PDF)
S8 File. Heatmap of histology signature scores of Brg1 +/- tumors. ssGSEA scores for histol-
ogy signatures on Brg1 +/- tumors in the context of the published dataset[9].
(PDF)
S9 File. Heatmap of histology signature scores of DMBA induced tumors. ssGSEA scores
for histology signatures on DMBA induced tumors in the context of the published dataset[9].
(PDF)
S10 File. Heatmap of histology signature scores of Erbb2-Knockin tumors. ssGSEA scores
for histology signatures on Erbb2-Knockin tumors in the context of the published dataset[9].
(PDF)
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S11 File. Heatmap of histology signature scores of Etv6-Nrrk3 tumors. ssGSEA scores for
histology signatures on Etv6-Ntrk3 tumors in the context of the published dataset[9].
(PDF)
S12 File. Heatmap of histology signature scores of IGFIR induced tumors. ssGSEA scores
for histology signatures on IGFIR induced tumors in the context of the published dataset[9].
(PDF)
S13 File. Heatmap of histology signature scores of Int3 induced tumors. ssGSEA scores for
histology signatures on Int3 induced tumors in the context of the published dataset[9].
(PDF)
S14 File. Heatmap of histology signature scores of LPA induced tumors. ssGSEA scores for
histology signatures on LPA induced tumors in the context of the published dataset[9].
(PDF)
S15 File. Heatmap of histology signature scores of Met induced tumors. ssGSEA scores for
histology signatures on Met induced tumors in the context of the published dataset[9].
(PDF)
S16 File. Heatmap of histology signature scores of Myc induced tumors. ssGSEA scores for
histology signatures on Myc induced tumors in the context of the published dataset[9].
(PDF)
S17 File. Heatmap of histology signature scores of Stat1 knockout tumors. ssGSEA scores
for histology signatures on Stat1 knockout induced tumors in the context of the published
dataset[9].
(PDF)
S18 File. Heatmap of histology signature scores of T-antigen induced tumors. ssGSEA
scores for histology signatures on T-antigen induced tumors in the context of the published
dataset[9].
(PDF)
S19 File. Heatmap of histology signature scores of WAP-TNP8 induced tumors. ssGSEA
scores for histology signatures on WAP-TNP8 induced tumors in the context of the published
dataset[9].
(PDF)
S20 File. Heatmap of histology signature scores of Wnt induced tumors. ssGSEA scores for
histology signatures on Wnt induced tumors in the context of the published dataset[9].
(PDF)
S21 File. Heatmap of histology signature scores of Neu induced tumors. ssGSEA scores for
histology signatures on Neu induced tumors in the context of the published dataset[9].
(PDF)
S22 File. Heatmap of histology signature scores of Notch induced tumors. ssGSEA scores
for histology signatures on Notch induced tumors in the context of the published dataset[9].
(PDF)
S23 File. Heatmap of histology signature scores of p18 induced tumors. ssGSEA scores for
histology signatures on p18 induced tumors in the context of the published dataset[9].
(PDF)
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S24 File. Heatmap of histology signature scores of p53 Null tumors. ssGSEA scores for his-
tology signatures on p53 Null tumors in the context of the published dataset[9].
(PDF)
S25 File. Heatmap of histology signature scores of Pik3CA tumors. ssGSEA scores for his-
tology signatures on Pik3CA tumors in the context of the published dataset[22].
(PDF)
S26 File. Heatmap of histology signature scores of PyMT induced tumors. ssGSEA scores
for histology signatures on PyMT induced tumors in the context of the published dataset[9].
(PDF)
S27 File. Heatmap of histology signature scores of Ras induced tumors. ssGSEA scores for
histology signatures on Ras induced tumors in the context of the published dataset[9].
(PDF)
S28 File. Heatmap of histology signature scores of RB/p107 knockout induced tumors.
ssGSEA scores for histology signatures on RB/p107 Knockout induced tumors in the context
of the published dataset[9].
(PDF)
S29 File. Single sample GSEA scores on individual mouse mammary tumor samples from
published datasets. Numeric GSEA scores on individual mouse mammary tumor samples
from published datasets[22, 102].
(XLSX)
S30 File. Statistical results from gene set enrichment analysis on groups of predicted
tumor histologies. Table showing all statistical details for gene set enrichment analysis results
related to Fig 3 and Fig 4.
(XLSX)
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